Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Retrospective Observational Study Characterizing Patients With Stage 2 Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

NCT07457580 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07457580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07457580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Retrospective Observational Study Characterizing Patients With Stage 2 Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
Lead sponsor
Sanofi
Phase
Observational
Overall status
Recruiting
Start date
March 16, 2026
Completion date
November 30, 2026
Enrollment
60 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes